Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Knut Pedersen leaves as CEO of Catella

Catella AB's (publ) President and CEO Knut Pedersen has informed the Board that he wishes to leave his role as CEO. He will continue in his current role during the notice period of a maximum of 6 months and will leave the position as CEO at the latest in conjunction with the Annual General Meeting.Knut Pedersen has been CEO of Catella since January 1, 2014.“During his six years as CEO, Knut Pedersen has successfully developed Catella into a pan-European finance group in real estate and alternative investments. It is my belief that Knut still have a lot to add to Catella, why my wish is

Scandinavian ChemoTech and its CEO Mohan Frick participates and presents at the Emerging Medtech Summit in California, USA

Scandinavian ChemoTech and its CEO Mohan Frick has been selected to present its Tumour Specific Electroporation at the Emerging Medtech Summit in California, USA. An event bringing together the top strategists, investors, and innovators within the Medtech industry.The summit is a 3-day event where ChemoTech and other medical device companies will present their innovations to some of the largest medical device companies and institutional investors, such as: Medtronic, Johnson & Johnson, Boston Scientific, Wells Fargo, China Bio Group and many others. After ChemoTech’s unique platform for

Cantargia presents novel preclinical data on antibody CAN04 at PEGS Europe conference

Cantargia AB today announce that new preclinical data on the antibody CAN04 is presented at the 11th annual PEGS (Protein & Antibody Engineering Summit) Europe conference, Nov 18-22 in Lisbon, Portugal. CAN04 is in clinical development for cancer and is designed to enhance immune-mediated tumor cell killing. The new results show that similar design applied to CAN04 surrogate antibodies enhance antitumor effects in experimental cancer models and further support for the strategy chosen.Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP).

Stockholm International Film Festival’s Audience Award 2019 goes to Jojo Rabbit

After the 30th edition of the Stockholm International Film Festival ended on Sunday, we now have the pleasure to announce that the 2019 Audience Award goes to Jojo Rabbit by Taika Waititi. Photo from Jojo Rabbit.  Each year, the Stockholm International Film Festival invites the festival audience to select the winner of one of the most important awards of the festival – the Audience Award. The audience nominates their favourite film by voting on the festival’s website.  The audience have been able to vote for their favourites from this year’s 150 films on the festival website

CEO Hosni Teque-Omeirat acquires shares in the company

Hosni Teque-Omeirat, CEO, has acquired 1,050,000 shares in the company. The purchases were made on Nasdaq First North Growth Market at an average price of SEK 0.54.   For further information contact: Hosni Teque-OmeiratCEO+46 70 225 18 77 hosni@spectrumone.com Certified Adviser: Mangold Fondkommission AB (556585-1267) Box 55 691 102 15 Stockholm Telefon: +46 8 503 015 50 ca@mangold.se www.mangold.se   About TargetEveryone TargetEveryone is a MARTECH company, enabling our clients to streamline their 1-1 digital marketing, content and experiences within one

Medivir reports last patient recruited to the phase Ia study of MIV-818 in liver cancer patients and initial dose determined for phase Ib

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) reports today that the ninth and final patient was recruited to the phase Ia study of MIV-818 in patients with advanced liver cancer. Based on data from phase Ia, the initial dose of MIV-818 for the phase Ib study has been determined at 200 mg / week. The dosage is given as 40 mg / day for five days. The phase I study with MIV-818, evaluating safety, tolerability and pharmacokinetics, consists of two parts: Phase Ia is an interpatient study while phase Ib has a classic 3 + 3 intrapatient dose-escalating design. A recommended dose

Recipharm Offers to Acquire Consort Medical to Become a Leading Inhalation Company and Top Five Global CDMO Player

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PUBLICATION IS NEITHER AN OFFER TO BUY OR SELL NOR AN INVITATION TO TENDER OR OFFER TO BUY OR SELL SHARES. Read the whole press release Recipharm Offers to Acquire Consort Medical to Become a Leading Inhalation Company and Top Five Global CDMO Player  Contact informationThomas Eldered, CEO, telephone: +46 8 602 52 10Tobias

Bublar Group introduces Photorealistic Rendering on the Sayduck Platform - launches with Vallila Interior as first customer

Bublar Group’s subsidiary Sayduck launches its Photorealistic Rendering feature with Vallila Interior, a leading Finnish home textile company using the Sayduck Platform to provide better visualization of its products. The new feature allows anybody to create high-resolution, photorealistic images from 3D models. With the surge of online shopping and social media the value of visual content in marketing and sales has become more important than ever before. A major problem for manye-commerce companies is the process of generating images and visual elements that power up and create a

Therapeutic Hypothermia After Cardiac Arrest with Non-Shockable Rhythm (HYPERION) Shows Statistically Significant Results In Cardiac Arrest Patients Presented At AHA

The HYPERION study was published in New England Journal of Medicine (NEJM) on October 5, 2019, with a first simultaneous presentation at the ESICM meeting in Berlin, Germany. The study was also presented and discussed at the ReSS meeting, part of the American Heart meeting in Philadelphia on Nov 16, 2019 as a special presentation by the Principal Investigator (PI) of the trial, Dr. Jean-Baptiste Lascarrou. Although, BrainCool was not part of the study, the results will have a large impact on the development of the temperature management market. In 2013, Targeted Temperature Management (

Brighter accelerates the commercialization of Actiste and carries out a rights issue – without trading of subscription rights – of approximately SEK 192 million

The Board of Directors of Brighter AB (publ) ("Brighter" or "the Company") today, with the support of the issuance authorization granted at the Annual General Meeting on May 9, 2019, has decided to carry out a new issue of approximately SEK 192 million ("the Offer") to the Company's shareholders. The terms and conditions have been designed to benefit and reward the Company's shareholders. The Offer does not constitute a customary rights issue, and applies only to those who hold shares in the Company as of the record date of December 12, 2019. Subscription without the support of

Interim Report - January – September, 2019 Redsense Medical AB (publ)

Quarter 3, 2019, showed an increase in sales of 103% versus same period last year and is the strongest in the company’s history. The growth is driven by the US market.Financial Summary Third quarter, 1 July – 30 September 2019 Redsense Medical group · Sales amounted to 4 645 KSEK (2 286), with an increase of 103% compared to 2018. · Earnings before interest and taxes amounted to -590 KSEK (-970). Redsense Medical AB · Net sales amounted to 3 257 KSEK (1 871). · Earnings before interest and taxes amounted to -895 KSEK (-530). 1 January – 30 September 2019

Autoliv Introduces Airbag that Prevents Passengers from Colliding

(Ogden, Utah USA, November 18, 2019) – Autoliv Inc. (NYSE: ALV and SSE: ALIVsdb), the worldwide leader in vehicle safety systems, today announced the development of a new front center airbag that is designed to save lives in side-impact crash situations. The airbag will be showcased at Autoliv’s Capital Markets Day held on November 19 at its technical center in Ogden, Utah. The head is one of the most frequently injured body regions in any road collision potentially resulting in devastating long-term consequences for the victim. For side collisions from the opposite side, the

BrainCool AB's (publ) rights issue oversubscribed

The subscription period in BrainCool's rights issue of a maximum of SEK 40.1 million ended on November 13. A total of SEK 42 million was subscribed, a subscription rate of 105%, of which 80% was subscribed with preferential rights. Consequently, no guarantee commitments were needed. BrainCool is allocated SEK 40.1 million before costs associated with the rights issue. CEO Martin Waleij comments; -        I would like to thank existing as well as new shareholders. With the proceeds from this rights issue, we are now continuing our marketing efforts in brain cooling in Germany and the

The use of antimicrobials in food-producing animals is decreasing, but additional investments are needed in the control of antimicrobial resistance

The joint FINRES-Vet 2018 report published by the Finnish Food Authority, the Finnish Medicines Agency Fimea and the University of Helsinki shows that the sales of antimicrobials used in food-producing animals has reduced in Finland in recent years. The antimicrobial resistance situation among bacteria causing disease in animals only or causing disease in both animals and humans has remained relatively good. On the other hand, observations have also been made on increased resistance to antimicrobials.The sales of antimicrobials intended for food-producing animals decreased by 18 per cent

Northmill hires new Chief Analytics and Credit Officer

- Georges Mansourati from Swedbank will be a key player in the fast-growing Swedish tech bank’s continued growthStockholm 18 November 2019: Northmill that recently received a Swedish license to conduct banking operations  continues to attract key competence and is hiring Georges Mansourati as the new Chief Analytics and Credit Officer. Georges has held several leading roles during his eleven years at Swedbank, such as risk analyst, trader, business owner for advanced analytics and as head

PolarCool AB (publ) signs an agreement with Zurich SC Lions in the Swiss hockey league

PolarCool AB (publ) has signed a cooperation agreement with Zurich SC Lions in the Swiss ice hockey league National League A, which is the top tier in the Swiss league system. Zurich SC Lions will evaluate PolarCap® System until the end of the current season.  Zürich SC Lions will thus become a reference team in the Swiss league, in a market where PolarCool (publ) also has good hopes of developing the business.  PolarCool's Erik Andersson comments;  - The fact that Dr. Gery Büsser, a very reputable doctor in this area, now chooses to include the use of PolarCap® System in his

InDex Pharmaceuticals presents at Redeye Life Science Day and Avanza Börsdag November 19, 2019

November 18, 2019 – InDex Pharmaceuticals Holding AB (publ) today announced that CEO Peter Zerhouni will present the company at Redeye Life Science Day at ROOTS@Downtown Camper by Scandic, Drottninggatan 28 in Stockholm at 08:35 CET and at Avanza Börsdag at Operaterrassen, Karl XII:s torg in Stockholm at 11:15 CET on November 19. Both presentations will be livestreamed.The presentation at Redeye Life Science Day can be followed at https://www.redeye.se/live/ls-day-2019 and will also be available afterwards on https://www.redeye.se/live/ls-day-2019 and on the company’s page in Redeye

Eurobattery Minerals announces update on Swedish explorations for battery minerals

Eurobattery Minerals AB (NGM; “BAT”), a growth company in the mining and exploration industry with the vision to help Europe become self-sufficient in ethical battery minerals, today announced an update on its explorations projects in Sweden. Similar to the project the company runs in Castriz in northern Spain where the results from the drilling campaign will be announced later in Q4, the focus for the Swedish projects is nickel, cobalt and copper, including also rare earth elements (REE), minerals that are all critical raw materials for the electric vehicle market in Europe. – I am

Redwood Pharma to present at BioStock Live in Stockholm on December 3, 2019

On December 3, CEO Martin Vidaeus from Redwood Pharma will present at BioStock Live (www.biostock.se) in Stockholm. The presentation will be in English. The program and registration for the event can be found on the event’s website, where a link to the live streamed broadcast of the presentation will also be available on December 3. Click on the following link to register: https://www.eventbrite.com/e/biostock-live-sthlm-december-3-biljetter-82498173257?aff=erelexpmlt About RP101RP101 is the company’s lead program for the development of a novel treatment of chronic dry eye disease

Stora Enso launches a new concept for constructing office buildings from wood

STORA ENSO OYJ PRESS RELEASE 18 November 2019 at 09:00 EETStora Enso is launching a new building concept that makes it easier for architects, engineers and developers to design office buildings from wood. The concept provides guidance on the use of prefabricated wooden building components. It also provides information to support the decision-making process for all major stakeholders involved in an office building project. Construction materials account for 40% of all materials used in the world today and 11% of global CO2 emissions. Wood components and building concepts are sustainable

Bittium Exhibits Its Innovative High-Tech Products and Solutions for Cardiology and Neurology at Medica 2019

Press Release Free for release on November 18, 2019 at 09:00 am (CET +1) Bittium Exhibits Its Innovative High-Tech Products and Solutions for Cardiology and Neurology at Medica 2019 Oulu, Finland, November 18, 2019 – Bittium exhibits its innovative products and solutions for cardiology and neurology at Medica 2019, the leading international trade fair for the medical sector, on November 18-21 in Dusseldorf, Germany. Bittium’s next generation’s high-tech solutions for cardiac and brain monitoring enable early detection of abnormalities in electrical activities, and thus speeding up

Photocure: First trial demonstrating reduced recurrence after flexible Blue Light Cystoscopy with Hexvix[®] in surveillance

Use of flexible Blue Light Cystoscopy at the first follow-up after TURBT* reduced the risk of tumor recurrence by 33% compared to white light alone. Randomized controlled multi-center study with 699 bladder cancer patients presented at Danish Urological Society meeting.Oslo, Norway November 18, 2019, Photocure ASA (PHO:OSE), is pleased to announce that results from new studies with flexible Blue Light Cystoscopy (BLC™) with Hexvix were presented at the annual meeting of the Danish Urology Society on Saturday, November 16. Results from a randomized controlled study in 699 patients from

Recipharm to communicate new financial targets on Capital Markets Day

Recipharm AB (publ) has continued to grow and will present its strategy for profitable growth moving forward, together with new financial targets from 2020, at today’s Capital Markets Day in Stockholm. The new financial targets are: · Recipharm’s target is to achieve a Compound Annual Growth Rate (CAGR) of at least 11%, with 2019 as base year. The growth will be organic as well as come from acquisitions.  · Recipharm’s target is to achieve an EBITA margin of at least 12% each year, measured as profit before financial items, tax and amortisation of intangible assets attributable

There are no items matching the current filter
There are no more items matching the current filter
Back to top